Neuphoria Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEUP research report →
About the company
Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders.
- CEO
- Spyridon Papapetropoulos
- IPO
- 2021
- Employees
- 8
- HQ
- Burlington, US
Price Chart
- Market Cap
- $18.27M
- P/E
- -0.31
- P/S
- -1.74
- P/B
- 0.62
- EV/EBITDA
- 0.05
- Div Yield
- 0.00%
- Gross Margin
- 104.75%
- Op Margin
- 250.04%
- Net Margin
- 263.11%
- ROE
- -109.66%
- ROIC
- -77.73%
- Revenue
- $15.65M · 0.00%
- Net Income
- $-369,632 · 98.41%
- EPS
- $-0.23 · -130.00%
- Op Income
- $-1,129,091
- FCF YoY
- 626.05%
- 52W High
- $21.40
- 52W Low
- $3.19
- 50D MA
- $4.82
- 200D MA
- $5.71
- Beta
- 0.75
- Avg Volume
- 65.96K
Get TickerSpark's AI analysis on NEUP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 20, 26 | Wilson David Ian | other | 8,537 |
| Jan 20, 26 | Davies Peter Miles Winston | other | 8,537 |
| Jan 20, 26 | Fisher Alan | other | 17,073 |
| Jan 20, 26 | Ryan Jane | other | 8,537 |
| Oct 21, 25 | Lynx1 Capital Management LP | buy | 639,110 |
| Oct 21, 25 | Lynx1 Capital Management LP | other | 0 |
| Aug 27, 25 | Papapetropoulos Spyros | other | 34,559 |
| Apr 16, 25 | Papapetropoulos Spyros | other | 27,000 |
| Apr 16, 25 | Papapetropoulos Spyros | other | 270,000 |
| Apr 16, 25 | Davies Peter Miles Winston | other | 6,783 |
Our NEUP coverage
Recent articles, reports, and earnings notes.
No research on NEUP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NEUP report →Similar companies
Peers in the same neighborhood.